This study is designed for people who have already received a treatment called ciltacabtagene autoleucel, or cilta-cel. Cilta-cel is a type of therapy that uses a person’s own immune cells, called T-cells, to fight cancer. Specifically, it targets a molecule called BCMA found on certain cancer cells. The study's goal is to track any long-term side effects people might experience after having cilta-cel treatment. Participants will not receive any new treatment during the study. Instead, researchers will monitor their health by checking for any delayed side effects or health issues. This will involve looking at any health problems participants may have had, lab test results, and physical exams. The study lasts up to 15 years with at least one check-up each year. Those eligible must have previously had at least one dose of cilta-cel in a company-sponsored study and must agree to be part of this long-term research.

• Study Duration: Up to 15 years with yearly follow-ups.
• No New Treatment: Data collection only, no new medications given.
• Participation Requirement: Previous cilta-cel treatment and consent to participate.